

# Contents

<b>1 Documentation and Correlation of Senologic Findings.....</b>	<b>1</b>
Renzo Brun del Re	
1.1 Introduction.....	1
1.2 Senometry .....	1
1.2.1 Material .....	1
1.3 Mapping Clinical Findings.....	1
1.4 Mapping Mammographic Lesions Smaller than 2 cm.....	3
1.4.1 Mapping the Lesion on the Mammogram.....	3
1.4.2 Transferring the Mammographic Dimensions onto the Breast.....	7
1.5 Intraoperative Senometric Needle Localization.....	15
1.6 Mapping Mammographic Lesions Larger than 2 cm.....	15
1.6.1 Mapping the Lesion on the Mammogram.....	15
1.6.2 Transferring Dimensions onto the Breast .....	17
1.7 Nonpalpable Lesion Detected by Ultrasound .....	19
1.8 Advantages of Senometry .....	21
References .....	21
<b>2 Comparison of Large-Core Vacuum-Assisted Breast Biopsy and Excision Systems .....</b>	<b>23</b>
Robin Wilson and Sanjay Kavia	
2.1 Introduction.....	23
2.2 Large-Core Biopsy Systems: Overview.....	24
2.2.1 Single Large-Core Biopsy System.....	24
2.2.2 Vacuum-Assisted Mamotomy Systems.....	26
2.3 Indications and Limitations.....	35
2.3.1 Limitations .....	36
2.3.2 Diagnostic Biopsy .....	37
2.3.3 Therapeutic Excision.....	38
2.3.4 Image-Guided Biopsy Technique.....	39

2.4	Conclusions.....	40
	References.....	40
<b>3</b>	<b>Sonographically Guided Vacuum-Assisted Breast Biopsy Using Handheld Mammotome.....</b>	<b>43</b>
	Luc Steyaert, Filip Van Kerkhove, and Jan W. Casselman	
3.1	Introduction.....	43
3.2	Equipment.....	43
3.3	Technique.....	48
3.4	Indications.....	67
3.4.1	Probably Benign or Indeterminate Nodular Lesions.....	68
3.4.2	Very Small Suspicious Lesions.....	70
3.4.3	Areas of Localized Attenuation.....	72
3.4.4	Isolated, Complex Fibrocystic Areas.....	73
3.4.5	Papillomas.....	75
3.4.6	Clusters of Microcalcifications.....	76
3.4.7	Lesions in Difficult Locations.....	82
3.4.8	Very Hard Lesions with Inconclusive Previous Biopsy or FNAC.....	82
3.4.9	Inadequate FNAC or Microbiopsy Results.....	82
3.4.10	Removal of Benign Lesions.....	82
3.4.11	Indications Discussed: Radial Scar, Large Intracystic Lesions.....	83
3.4.12	Other Indications.....	85
3.5	Processing the Cores.....	85
3.6	Needle Size.....	88
3.7	Clip Placement.....	90
3.8	US Versus Mammographic Guidance.....	90
3.9	Results.....	92
	References.....	93
<b>4</b>	<b>The Vacora Biopsy System.....</b>	<b>97</b>
	R. Schulz-Wendtland	
4.1	Introduction.....	97
4.2	Technique.....	97
4.3	Indications and Contraindications.....	98
4.3.1	US-Guided Transcutaneous Vacuum Biopsy.....	98
4.3.2	Stereotactic Vacuum Biopsy.....	101
4.3.3	MRI-Guided Vacuum Biopsy.....	101
4.4	Side Effects.....	101
4.5	Results.....	101
4.6	Limitations.....	102
4.7	Practical Hints.....	102
	References.....	102

<b>5 Available Stereotactic Systems for Breast Biopsy</b> .....	105
Ossi R. Köchli	
5.1 Introduction.....	105
5.1.1 Prone Position Techniques .....	105
5.1.2 Upright Systems.....	109
5.2 Cost of the Systems.....	112
5.3 Cost of the Procedures .....	112
References .....	113
<b>6 MRI-Guided Minimally Invasive Breast Procedures</b> .....	115
Harald Marcel Bonel	
6.1 Introduction: Role of MR Mammography .....	115
6.1.1 Indications.....	116
6.1.2 Technique and Practical Tips.....	117
6.1.3 Limitations .....	126
6.2 Conclusion .....	128
References .....	128
<b>7 Ductoscopy of Intraductal Neoplasia of the Breast</b> .....	129
Michael Hünerbein, Matthias Raubach, Y.Y. Dai, and Peter M. Schlag	
7.1 Introduction.....	129
7.2 Methods for Sampling Intraductal Breast Cells.....	129
7.2.1 Technique of Ductoscopy.....	130
7.2.2 Ductoscopic Biopsy .....	132
7.2.3 Ductoscopy in Women with Nipple Discharge .....	132
7.2.4 Ductoscopy in Breast Cancer.....	133
7.3 Summary .....	134
References.....	134
<b>8 Pathology of Breast Tissue Obtained in Minimally Invasive Biopsy Procedures</b> .....	137
Gad Singer and Sylvia Stadlmann	
8.1 Introduction.....	137
8.2 Pathology of Breast Disease in Minimally Invasive Biopsies.....	137
8.3 Benign Epithelial Lesions .....	138
8.3.1 Periductal Mastitis.....	138
8.3.2 Fibrocystic Change.....	138
8.3.3 Sclerosing Adenosis.....	139
8.3.4 Columnar Cell Lesions .....	140
8.3.5 Usual-Type Epithelial Hyperplasia .....	140
8.3.6 Lobular Neoplasia .....	141

8.4	Fibroepithelial Lesions.....	142
8.4.1	Fibroadenoma.....	142
8.4.2	Phyllodes Tumor.....	143
8.4.3	Benign Papillary Lesions .....	143
8.5	Malignant Noninvasive Lesions.....	144
8.6	Invasive Carcinoma.....	145
8.7	Grading of Breast Carcinoma .....	146
8.8	Predictive Factors in MIBS .....	147
	References.....	147
<b>9</b>	<b>Limitations of Minimally Invasive Breast Biopsy.....</b>	<b>149</b>
	Mathias K. Fehr	
9.1	Technical Failures.....	149
9.2	Underestimation of Breast Pathology on Minimally Invasive Breast Biopsy Specimens.....	149
	References.....	155
<b>10</b>	<b>Advances in Breast Imaging: A Dilemma or Progress? .....</b>	<b>159</b>
	Daniel Flöry, Michael W. Fuchsjaeger, Christian F. Weisman, and Thomas H. Helbich	
10.1	Introduction.....	159
10.2	Ultrasound.....	159
10.2.1	Multiplanar Display Mode .....	161
10.2.2	Niche Mode View.....	161
10.2.3	Surface Mode.....	161
10.2.4	Transparency Mode.....	161
10.2.5	Static 3D Volume Contrast Imaging.....	162
10.2.6	4D Volume Contrast Imaging.....	162
10.2.7	Inversion Mode .....	163
10.2.8	Volume Calculation.....	163
10.2.9	Tomographic Ultrasound Imaging .....	163
10.2.10	Glass Body Rendering .....	164
10.2.11	Power Doppler, Color Doppler, and High-Definition Flow .....	164
10.2.12	Extended View Documentation.....	165
10.2.13	Conclusion .....	167
10.3	Magnetic Resonance Imaging.....	167
10.3.1	1.5-Tesla Systems and Gadopentetate.....	167
10.3.2	3.0-Tesla Systems.....	168
10.3.3	Macromolecular Contrast Agents.....	168
10.3.4	Tumor-Specific Contrast Agents.....	170
10.3.5	Functional Breast Imaging Techniques (Spectroscopy, Diffusion-Weighted Imaging) .....	171

10.4	Positron Emission Tomography.....	172
10.4.1	Imaging of Cellular Proliferation and Apoptosis.....	172
10.4.2	Receptor Imaging.....	173
10.5	Optical Imaging.....	173
10.5.1	Imaging of Hemoglobin.....	174
10.5.2	CTLM Device.....	174
10.5.3	Optical Imaging of Extrinsic Contrast Agents.....	175
10.6	Electrical Impedance Scanning.....	176
10.6.1	Targeted EIS with TransScan TS2000.....	177
10.6.2	Screening EIS with T-Scan 2000ED.....	179
10.7	Conclusion.....	180
	References.....	180
<b>11</b>	<b>Cost–Benefit Analyses.....</b>	<b>183</b>
	Renzo Brun del Re and Regula E. Bürki	
11.1	Introduction.....	183
11.2	Frequency of Mammography.....	183
11.3	Recall Rate.....	184
11.3.1	Recall Rate in Screening Programs.....	184
11.3.2	Recall Rate Outside of Screening Programs.....	185
11.4	Distribution of Further Investigations.....	185
11.4.1	Open (Surgical) Biopsy.....	185
11.4.2	Substitution of Open Biopsies.....	185
11.4.3	Substitution of Other Diagnostic Procedures.....	186
11.5	Trends and Scenarios.....	187
11.6	Comparison of Costs.....	187
11.6.1	Costs and Savings.....	189
11.7	Decision Makers Have Changed.....	190
11.8	Conclusions.....	192
	References.....	192
<b>12</b>	<b>Systematic Review and Meta-analysis of Recent Data.....</b>	<b>195</b>
	Renzo Brun del Re and Regula E. Bürki	
12.1	Evidence for the Clinical Relevance of Minimally Invasive Breast Biopsy.....	195
12.1.1	Older Systematic Reviews.....	195
12.2	Literature Search Methods.....	195
12.2.1	Evidence on Performance.....	195
12.2.2	Evidence on Risks and Safety.....	197
12.2.3	Presentation and Analysis of the Data.....	197
12.3	Presentation and Analysis of the Data.....	200
12.3.1	Evidence Used.....	200
12.3.2	Results.....	207

---

12.4	Safety of MIBB .....	212
12.4.1	Open Biopsy as Gold Standard .....	212
12.4.2	Fourteen-G Core Biopsies and 11-G Vacuum-Assisted Biopsies .....	212
12.4.3	Conclusions on the Safety of MIBB .....	215
12.5	Quality of Life (HRQoL) .....	215
12.6	Summary and Discussion of the MIBB Data Presented .....	217
12.7	Conclusions .....	220
	References .....	222